Raras
Buscar doenças, sintomas, genes...
Síndrome Noonan
ORPHA:648CID-10 · Q87.1CID-11 · LD2F.15DOENÇA RARA

A Síndrome de Noonan (SN) é caracterizada por baixa estatura, dismorfismo facial típico e defeitos cardíacos congênitos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Síndrome de Noonan (SN) é caracterizada por baixa estatura, dismorfismo facial típico e defeitos cardíacos congênitos.

Pesquisas ativas
18 ensaios
52 total registrados no ClinicalTrials.gov
Publicações científicas
2.442 artigos
Último publicado: 2026 Apr 16
Medicamentos
3 registrados
SOMATROPIN, SIMVASTATIN, MECASERMIN

Tem tratamento?

3 medicamentos registrados
Ver detalhes, fases e interações →
SOMATROPINSIMVASTATINMECASERMIN

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Antenatal
+ childhood, infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 35%
Centros em: PA, PR, SC, RS, ES +10CID-10: Q87.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

😀
Face
29 sintomas
🧬
Pele e cabelo
23 sintomas
🦴
Ossos e articulações
23 sintomas
❤️
Coração
20 sintomas
🧠
Neurológico
18 sintomas
👁️
Olhos
15 sintomas

+ 94 sintomas em outras categorias

Características mais comuns

90%prev.
Pectus excavatum
Muito frequente (99-80%)
90%prev.
Testa alta
Muito frequente (99-80%)
90%prev.
Prega cutânea nucal espessada
Muito frequente (99-80%)
90%prev.
Pectus carinatum
Muito frequente (99-80%)
90%prev.
Face triangular
Muito frequente (99-80%)
90%prev.
Micrognatia
Muito frequente (99-80%)
267sintomas
Muito frequente (29)
Frequente (21)
Ocasional (19)
Muito raro (1)
Sem dados (197)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 267 características clínicas mais associadas, ordenadas por frequência.

Pectus excavatum
Muito frequente (99-80%)90%
Testa altaHigh forehead
Muito frequente (99-80%)90%
Prega cutânea nucal espessadaThickened nuchal skin fold
Muito frequente (99-80%)90%
Pectus carinatum
Muito frequente (99-80%)90%
Face triangularTriangular face
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.442PubMed
Últimos 10 anos200publicações
Pico2025147 papers
Linha do tempo
2026Hoje · 2026🧪 1990Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

17 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

MRASRas-related protein M-RasDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival (PubMed:16630891, PubMed:28289718, PubMed:35768504, PubMed:35830882, PubMed:35831509, PubMed:36175670). Core component of the SHOC2-MRAS-PP1c (SMP) holophosphatase complex that regulates the MAPK pathway activation (PubMed:16630891, PubMed:35768504, PubMed:35830882, PubMed:35831509, PubMed:36175670). The formation of the SMP complex only occurs when MRAS is GTP-bound (PubMed:35768504, PubMed:358308

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
RAF activationSHOC2 M1731 mutant abolishes MRAS complex functionGain-of-function MRAS complexes activate RAF signaling
MECANISMO DE DOENÇA

Noonan syndrome 11

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. NS11 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
114.6 TPM
Brain Nucleus accumbens basal ganglia
69.5 TPM
Brain Anterior cingulate cortex BA24
66.6 TPM
Brain Frontal Cortex BA9
64.4 TPM
Córtex cerebral
63.5 TPM
OUTRAS DOENÇAS (3)
RASopathyNoonan syndrome 11Noonan syndrome
HGNC:7227UniProt:O14807
LRRC56Leucine-rich repeat-containing protein 56Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for the assembly of dynein arms

LOCALIZAÇÃO

Cell projection, cilium

MECANISMO DE DOENÇA

Ciliary dyskinesia, primary, 39

A form of primary ciliary dyskinesia, a disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. Some patients exhibit randomization of left-right body asymmetry and situs inversus. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. CILD39 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
62.5 TPM
Pituitária
28.0 TPM
Brain Nucleus accumbens basal ganglia
12.2 TPM
Cerebelo
11.0 TPM
Cérebro - Hemisfério cerebelar
9.2 TPM
OUTRAS DOENÇAS (4)
ciliary dyskinesia, primary, 39Costello syndromeNoonan syndromeprimary ciliary dyskinesia
HGNC:25430UniProt:Q8IYG6
MAPK1Mitogen-activated protein kinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, c

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, spindleNucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasmMembrane, caveolaCell junction, focal adhesion

VIAS BIOLÓGICAS (10)
Negative regulation of MAPK pathwayRAF-independent MAPK1/3 activationSignaling by LTK in cancerAdvanced glycosylation endproduct receptor signalingSignaling by BRAF and RAF1 fusions
MECANISMO DE DOENÇA

Noonan syndrome 13

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. NS13 inheritance is autosomal dominant. There is considerable variability in severity.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Nucleus accumbens basal ganglia
62.5 TPM
Cérebro - Hemisfério cerebelar
57.4 TPM
Brain Frontal Cortex BA9
49.8 TPM
Brain Caudate basal ganglia
44.7 TPM
Nervo tibial
42.5 TPM
OUTRAS DOENÇAS (2)
Noonan syndrome 13chromosome 22q11.2 deletion syndrome, distal
HGNC:6871UniProt:P28482
CBLE3 ubiquitin-protein ligase CBLDisease-causing germline mutation(s) inRestrito
FUNÇÃO

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567, PubMed:40101708). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, Pu

LOCALIZAÇÃO

CytoplasmCell membraneCell projection, ciliumGolgi apparatus

VIAS BIOLÓGICAS (10)
TGF-beta receptor signaling activates SMADsPTK6 Regulates RTKs and Their Effectors AKT1 and DOK1Spry regulation of FGF signalingEGFR downregulationNegative regulation of MET activity
MECANISMO DE DOENÇA

Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia

A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.

OUTRAS DOENÇAS (4)
CBL-related disorderjuvenile myelomonocytic leukemiaNoonan syndromeaggressive systemic mastocytosis
HGNC:1541UniProt:P22681
LZTR1Leucine-zipper-like transcriptional regulator 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras (K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) (PubMed:30442762, PubMed:30442766, PubMed:30481304). Is a negative regulator of RAS-MAPK signaling that acts by controlling Ras levels and decreasing Ras association with membranes (PubMed:30442762, PubMed:30442766, PubMed:30481304)

LOCALIZAÇÃO

Endomembrane systemRecycling endosomeGolgi apparatus

MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
76.5 TPM
Nervo tibial
68.8 TPM
Útero
67.8 TPM
Cervix Ectocervix
65.1 TPM
Cervix Endocervix
61.7 TPM
OUTRAS DOENÇAS (9)
Noonan syndrome 10RASopathyNoonan syndrome 2cafe au lait spots, multiple
HGNC:6742UniProt:Q8N653
RASA2Ras GTPase-activating protein 2Disease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Inhibitory regulator of the Ras-cyclic AMP pathway. Binds inositol tetrakisphosphate (IP4)

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear region

VIAS BIOLÓGICAS (1)
Regulation of RAS by GAPs
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
24.6 TPM
Cérebro - Hemisfério cerebelar
24.0 TPM
Cervix Endocervix
23.6 TPM
Cerebelo
23.0 TPM
Cervix Ectocervix
22.3 TPM
OUTRAS DOENÇAS (1)
Noonan syndrome
HGNC:9872UniProt:Q15283
RIT1B-cell lymphoma/leukemia 11BDisease-causing germline mutation(s) (gain of function) inAltamente restrito
FUNÇÃO

Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes (PubMed:16809611). Tumor-suppressor that r

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Signalling to p38 via RIT and RIN
MECANISMO DE DOENÇA

Immunodeficiency 49, severe combined

A form of severe combined immunodeficiency characterized by severe T-cell lymphopenia, no detectable T-cell receptor excision circles, no naive helper CD4+ T-cells, and impaired T-cell proliferative response. In addition to primary immunodeficiency, affected individuals manifest multiple abnormal systemic features, including severe delayed psychomotor development, intellectual disability, spastic quadriplegia, and craniofacial abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
32.2 TPM
Esôfago - Mucosa
32.1 TPM
Linfócitos
30.2 TPM
Vagina
28.8 TPM
Sangue
27.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
Noonan syndrome 8RASopathyNoonan syndrome
HGNC:10023UniProt:Q9C0K0
KRASGTPase KRasDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
RAF1RAF proto-oncogene serine/threonine-protein kinaseDisease-causing germline mutation(s) (gain of function) inAltamente restrito
FUNÇÃO

Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and

LOCALIZAÇÃO

CytoplasmCell membraneMitochondrionNucleus

VIAS BIOLÓGICAS (5)
IFNG signaling activates MAPKsCD209 (DC-SIGN) signalingStimuli-sensing channelsGP1b-IX-V activation signallingRap1 signalling
MECANISMO DE DOENÇA

Noonan syndrome 5

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
152.2 TPM
Artéria tibial
139.4 TPM
Cérebro - Hemisfério cerebelar
134.9 TPM
Sangue
131.1 TPM
Ovário
129.4 TPM
OUTRAS DOENÇAS (9)
Noonan syndrome 5LEOPARD syndrome 2dilated cardiomyopathy 1NNNoonan syndrome
HGNC:9829UniProt:P04049
NRASGTPase NRasDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsNeutrophil degranulation
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
77.3 TPM
Fibroblastos
52.5 TPM
Skin Not Sun Exposed Suprapubic
25.1 TPM
Esôfago - Mucosa
24.4 TPM
Skin Sun Exposed Lower leg
23.4 TPM
OUTRAS DOENÇAS (13)
neurocutaneous melanocytosislarge congenital melanocytic nevusthyroid cancer, nonmedullary, 2colorectal cancer
HGNC:7989UniProt:P01111
SOS1Son of sevenless homolog 1Disease-causing germline mutation(s) (gain of function) inAltamente restrito
FUNÇÃO

Promotes the exchange of Ras-bound GDP by GTP (PubMed:8493579). Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF (PubMed:17339331). Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity (By similarity)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Interleukin-15 signalingRAC1 GTPase cycleG alpha (12/13) signalling eventsNRAGE signals death through JNKActivation of RAC1
MECANISMO DE DOENÇA

Fibromatosis, gingival, 1

A form of hereditary gingival fibromatosis, a rare condition characterized by a slow, progressive overgrowth of the gingiva. The excess gingival tissue can cover part of or the entire crown, and can result in diastemas, teeth displacement, or retention of primary or impacted teeth. GINGF1 is usually transmitted as an autosomal dominant trait, although sporadic cases are common.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
34.8 TPM
Tecido adiposo
30.5 TPM
Artéria tibial
30.0 TPM
Útero
29.4 TPM
Aorta
27.6 TPM
OUTRAS DOENÇAS (5)
Noonan syndrome 4fibromatosis, gingival, 1Noonan syndromeRASopathy
HGNC:11187UniProt:Q07889
RRAS2Ras-related protein R-Ras2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

GTP-binding protein with GTPase activity, involved in the regulation of MAPK signaling pathway and thereby controlling multiple cellular processes (PubMed:31130282, PubMed:31130285, PubMed:39809765). Regulates craniofacial development (PubMed:31130282, PubMed:31130285)

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
RND1 GTPase cycle
MECANISMO DE DOENÇA

Ovarian cancer

The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
66.9 TPM
Linfócitos
43.5 TPM
Pulmão
22.4 TPM
Aorta
21.0 TPM
Testículo
19.7 TPM
OUTRAS DOENÇAS (3)
Noonan syndromeRASopathynoonan syndrome 12
HGNC:17271UniProt:P62070
SOS2Son of sevenless homolog 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as guanine nucleotide exchange factor (GEF) for RAS proteins. Catalyzes the GDP-to-GTP exchange, resulting in an increase of the active GTP-bound form of HRAS (PubMed:20639119). Acts as a key modulator of PI3K-AKT signaling

LOCALIZAÇÃO

VIAS BIOLÓGICAS (5)
G alpha (12/13) signalling eventsNRAGE signals death through JNKInterleukin-15 signalingActivation of RAC1RAC1 GTPase cycle
MECANISMO DE DOENÇA

Noonan syndrome 9

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
25.7 TPM
Testículo
24.0 TPM
Artéria tibial
23.2 TPM
Útero
21.9 TPM
Brain Spinal cord cervical c-1
21.6 TPM
OUTRAS DOENÇAS (3)
Noonan syndrome 9RASopathyNoonan syndrome
HGNC:11188UniProt:Q07890
BRAFSerine/threonine-protein kinase B-rafDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
PTPN11Tyrosine-protein phosphatase non-receptor type 11Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742426, PubMed:28074573, PubMed:32184441). Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)Spry regulation of FGF signalingRegulation of IFNA/IFNB signalingRegulation of IFNG signalingGPVI-mediated activation cascade
MECANISMO DE DOENÇA

LEOPARD syndrome 1

A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
111.4 TPM
Brain Spinal cord cervical c-1
108.7 TPM
Artéria tibial
90.4 TPM
Substância negra
83.1 TPM
Aorta
73.7 TPM
OUTRAS DOENÇAS (7)
juvenile myelomonocytic leukemiaNoonan syndrome 1metachondromatosisLEOPARD syndrome 1
HGNC:9644UniProt:Q06124
RRASRas-related protein R-RasCandidate gene tested inTolerante
FUNÇÃO

GTP-binding protein with GTPase activity, likely involved in the regulation of MAPK signaling pathway and thereby controlling multiple cellular processes (PubMed:39809765). Regulates the organization of the actin cytoskeleton (PubMed:16537651, PubMed:18270267). With OSPBL3, modulates integrin beta-1 (ITGB1) activity (PubMed:18270267)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Sema4D mediated inhibition of cell attachment and migrationSEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
775.9 TPM
Aorta
705.3 TPM
Artéria coronária
603.3 TPM
Esôfago - Junção
466.8 TPM
Esôfago - Muscular
441.8 TPM
OUTRAS DOENÇAS (2)
Noonan syndromejuvenile myelomonocytic leukemia
HGNC:10447UniProt:P10301
SPRED2Sprouty-related, EVH1 domain-containing protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Negatively regulates Ras signaling pathways and downstream activation of MAP kinases (PubMed:15683364, PubMed:34626534). Recruits and translocates NF1 to the cell membrane, thereby enabling NF1-dependent hydrolysis of active GTP-bound Ras to inactive GDP-bound Ras (PubMed:34626534). Inhibits fibroblast growth factor (FGF)-induced retinal lens fiber differentiation, probably by inhibiting FGF-mediated phosphorylation of ERK1/2 (By similarity). Inhibits TGFB-induced epithelial-to-mesenchymal trans

LOCALIZAÇÃO

Cell membraneCytoplasmic vesicle, secretory vesicle membraneCytoplasm

VIAS BIOLÓGICAS (2)
Regulation of RAS by GAPsRAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Noonan syndrome 14

A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. NS14 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
34.2 TPM
Tireoide
30.9 TPM
Mama
30.5 TPM
Adipose Visceral Omentum
30.4 TPM
Tecido adiposo
29.7 TPM
OUTRAS DOENÇAS (2)
Noonan syndrome 14Noonan syndrome
HGNC:17722UniProt:Q7Z698

Medicamentos e terapias

SOMATROPINPhase 3

Mecanismo: Growth hormone receptor agonist

SIMVASTATINPhase 3

Mecanismo: HMG-CoA reductase inhibitor

MECASERMINPhase 2

Mecanismo: Insulin-like growth factor I receptor agonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

344 variantes patogênicas registradas no ClinVar.

🧬 MRAS: NM_001085049.3(MRAS):c.28A>G (p.Asn10Asp) ()
🧬 MRAS: GRCh37/hg19 3q22.1-29(chr3:132561657-197851986)x3 ()
🧬 MRAS: NM_001085049.3(MRAS):c.479C>T (p.Pro160Leu) ()
🧬 MRAS: NM_001085049.3(MRAS):c.399G>C (p.Leu133Phe) ()
🧬 MRAS: GRCh37/hg19 3q22.1-25.1(chr3:131235568-150065289)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 4,300 variantes classificadas pelo ClinVar.

3225
1075
VUS (75.0%)
Benigna (25.0%)
VARIANTES MAIS SIGNIFICATIVAS
PTPN11: NM_002834.5(PTPN11):c.1173C>A (p.Ser391Arg) [Uncertain significance]
LOC130005368: NM_012250.6(RRAS2):c.55G>A (p.Val19Met) [Uncertain significance]
SHOC2: NM_007373.4(SHOC2):c.146A>T (p.Asp49Val) [Uncertain significance]
KRAS: NM_033360.4(KRAS):c.476del (p.Leu159fs) [Uncertain significance]
SOS2: NM_006939.4(SOS2):c.3760A>G (p.Thr1254Ala) [Uncertain significance]

Vias biológicas (Reactome)

125 vias biológicas associadas aos genes desta condição.

RAF activation SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling phospho-PLA2 pathway RAF-independent MAPK1/3 activation MAPK1 (ERK2) activation Signaling by NODAL Spry regulation of FGF signaling Signaling by Activin Golgi Cisternae Pericentriolar Stack Reorganization Frs2-mediated activation ERK/MAPK targets ERKs are inactivated Regulation of actin dynamics for phagocytic cup formation Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence FCERI mediated MAPK activation Regulation of HSF1-mediated heat shock response NCAM signaling for neurite out-growth Recycling pathway of L1 RSK activation Signal transduction by L1 Activation of the AP-1 family of transcription factors Thrombin signalling through proteinase activated receptors (PARs) Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate NADPH Oxidases Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants Regulation of RAS by GAPs Formation of the embryonic stem cell BAF (esBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) SOS-mediated signalling Activation of RAS in B cells SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R Ca2+ pathway Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling Stimuli-sensing channels Rap1 signalling GP1b-IX-V activation signalling MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants IFNG signaling activates MAPKs SHC-mediated cascade:FGFR4 NRAGE signals death through JNK Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated Ca+2 mobilization GRB2:SOS provides linkage to MAPK signaling for Integrins G alpha (12/13) signalling events Activation of RAC1 RND1 GTPase cycle Interleukin-15 signaling RAC1 GTPase cycle ARMS-mediated activation Signalling to p38 via RIT and RIN PI3K Cascade MAPK3 (ERK1) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling GAB1 signalosome PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion Sema4D mediated inhibition of cell attachment and migration FGFRL1 modulation of FGFR1 signaling RAS signaling downstream of NF1 loss-of-function variants

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 34
2Fase 23
·Pré-clínico16
Medicamentos catalogadosEnsaios clínicos· 3 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Noonan

Centros de Referência SUS

24 centros habilitados pelo SUS para Síndrome Noonan

Centros para Síndrome Noonan

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

15 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

52 ensaios clínicos encontrados, 18 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.354 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.354

#1

Novel Variants in PTPN11, NF1, RASA2, and MAP2K1: Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort.

Clinical genetics2026 Mar 19

RASopathies are a group of genetically heterogeneous developmental disorders caused by germline variants affecting the RAS/MAPK signaling pathway. These disorders display overlapping clinical features and diverse molecular mechanisms. This study aimed to evaluate the clinical and molecular spectrum of patients diagnosed with RASopathies, with a particular focus on novel and rare variants. A retrospective, multicenter study was conducted on patients with clinically suspected RASopathy and diagnosed by targeted Next Generation Sequencing analysis between 2021 and 2024. Variants were classified according to ACMG criteria, and clinical data were reviewed for genotype-phenotype correlations. Among 23 patients (14 males, 9 females), 15 (65.2%) had Noonan syndrome, five (21.7%) Neurofibromatosis Type 1, two (8.7%) Cardio-facio-cutaneous syndrome, and one (4.3%) Neurofibromatosis-Noonan syndrome. The most frequent clinical findings were craniofacial dysmorphism (91.3%), musculoskeletal anomalies (82.6%), and cutaneous features (78.3%). A total of 24 heterozygous variants were identified in seven genes: PTPN11 (45.8%), NF1 (25%), LZTR1 (12.5%), and RASA2, SOS1, MAP2K1, and BRAF (each 4.2%). Four novel variants were detected (PTPN11 c.853 + 4A>G, RASA2 p.E71D, NF1 p.W784Mfs*10, MAP2K1 p.A106T). This study highlights the clinical and molecular heterogeneity of RASopathies and expands the variant spectrum with novel and rare pathogenic alterations. The identification of new variants, particularly in rarely implicated genes such as RASA2, underlines the diagnostic value of comprehensive NGS-based testing and the need for individualized, multidisciplinary clinical management.

#2

Phosphoproteomics elucidates the functional impact of the PTPN11 p.Asn308Ser variant in a Noonan syndrome pedigree.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences2026 Feb 17

Noonan syndrome (NS) is a common autosomal dominant disorder with considerable clinical heterogeneity. Mutations in the PTPN11 gene, encoding the SHP2 protein, constitute the most prevalent genetic cause of NS. Genetic sequencing of a pedigree exhibiting typical facial dysmorphism and short stature identified the same heterozygous PTPN11 variant (NM_001330437.2: c.923 A > G, p.Asn308Ser) in all seven affected individuals, co-segregating with the phenotype. Using a multi-level approach that integrated experimental structural analysis, molecular dynamics simulations, protein-protein interaction network analysis, quantitative phosphoproteomics, and functional validation in cellular models, we systematically elucidated the pathogenic mechanism of the p.Asn308Ser mutation. This revealed that the mutation disrupts critical hydrogen bonds and remodels the interaction network. This change enhances conformational heterogeneity and shifts the protein into an activated "open" state. Consequently, the mutation strengthens interactions with hub proteins, such as GRB2 and SRC, resulting in sustained RAS/MAPK activation. Phosphoproteomic analysis showed that the mutation induces extensive phosphorylation events, with differentially phosphorylated proteins significantly enriched in the nucleus, particularly in pathways related to chromatin organization and ATP-dependent chromatin remodeling. Further functional validation indicated that aberrantly activated ERK may phosphorylate chromatin remodeling complexes such as SWI/SNF, thereby directly connecting cytoplasmic signaling to aberrant epigenetic regulation in the nucleus. This study delineates the complete pathogenic axis of the PTPN11 p.Asn308Ser mutation, spanning atomic conformational changes and sustained signaling activation to aberrant nuclear chromatin remodeling. These findings extend the understanding of NS pathophysiology to the epigenetic level and provide a theoretical foundation for future interventions targeting both signaling pathways and chromatin states.

#3

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways.

Cells2026 Jan 20

The oncogene KRAS drives tumor growth by activating pathways such as MAPK and PI3K-AKT in a constitutive manner. Although direct KRAS inhibitors exist, they are often limited in clinical use due to therapeutic resistance and toxicity. Therefore, alternative combinatorial therapeutic strategies are urgently needed. This study examined the knockout of five KRAS-related proteins-galectin-3 (GAL3), phosphodiesterase delta (PDEδ), nucleophosmin (NPM1), IQ motif-containing GTPase-activating protein 1 (IQGAP1), and SHOC2-using CRISPR-Cas9 in adenocarcinoma cell lines harboring the KRAS(G12V) oncogenic mutation, as well as in the noncancerous HEK-293 cell line. These proteins act as critical modulators that regulate KRAS activity, cellular localization, and that of its downstream signaling components. We analyzed the downstream activation of ERK and AKT kinases and evaluated subsequent cancer cell proliferation. Knockout of GAL3 and PDEδ was highly effective, significantly reducing MAPK and PI3K-AKT pathway activity and substantially impairing cell proliferation. SHOC2 knockout selectively and potently disrupted MAPK activation, while NPM1 knockout resulted in the complex, reciprocal modulation of the two major pathways. Notably, knocking out IQGAP1 enhanced PI3K-AKT and mTORC2-AKT signaling without affecting the MAPK pathway. These distinct modulatory roles highlight the non-redundant functions of the accessory proteins. In conclusion, our findings establish GAL3 and PDEδ, two KRAS-associated proteins, as promising combinatorial drug targets. Targeting these modulators provides an effective alternative strategy to overcome resistance mechanisms and enhance the clinical utility of existing KRAS inhibitors.

#4

Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.

European journal of pediatrics2026 Jan 24

The variety of genes associated with Noonan syndrome spectrum disorders (NSSD) is expanding, and real-life experience with its management is increasing; however, phenotypic differences among genotypes remain poorly defined. We aimed to assess clinical characteristics and response to growth hormone (GH) therapy in a genetically confirmed, single-country multicentre NSSD cohort. We included 101 patients with NSSD (56 males) from six centres: 76 with (likely) pathogenic PTPN11 variants, 7 with SOS1 variants, and 18 with other gene variations. All completed at least one year of GH therapy; 23 reached final height. Parental heights were below average (fathers: - 0.33 SDS [- 1.19; 0.39], p < 0.01; mothers: - 0.68 SDS [- 1.47; 0.12], p < 0.001; medians [IQR]). SOS1-NS patients were born earlier (gestational week 36 [31; 37]) compared to PTPN11-NS. Birth length (- 1.23 SDS [- 1.74; - 0.57]) was more reduced than weight (- 0.29 SDS [- 1.10; 0.54]; p < 0.0001); PTPN11-NS/SOS1-NS had the lowest birth weights (p < 0.05). GH was started at 6.4 years (3.8; 9.5), with baseline height-SDS - 2.92 (- 3.64; - 2.47). Median annual height-SDS increments were similar across genotypes: 0.61 (year 1; n = 101), 0.28 (year 2; n = 92), 0.21 (year 3; n = 77), 0.07 (year 4; n = 63), and 0.09 (year 5; n = 41), leading to height-SDS - 1.97 (- 2.81; - 1.42) after 5 years. Menarche occurred at age 15.7 (13.8; 17.2) years (n = 13), and final height-SDS (available in 23 patients) reached - 1.68 (- 2.65; - 0.41). Conclusions Growth restriction in NSSD begins prenatally, especially in PTPN11-NS and SOS1-NS. GH therapy was associated with improved height SDS, with the largest height gains observed before puberty. Earlier treatment initiation may therefore be beneficial for growth outcomes. What is Known: • Noonan syndrome spectrum disorders (NSSD) are genetically heterogeneous, with pathogenic variants in the PTPN11 and SOS1 genes being most prevalent. Phenotypic differences among genotypes remain poorly defined. • Short stature is a key NSSD feature. Growth hormone (GH) therapy is beneficial, but prior studies lacked genetic justification or had limited sample sizes. What is New: • We analysed perinatal data and real-life GH outcomes in 101 genetically confirmed NSSD cases. • SOS1-NS was linked to prematurity. Birth length was more reduced than weight across genotypes; PTPN11/SOS1 cases had the lowest birth weights. GH therapy was associated with an increase in height SDS from - 2.92 to - 1.97 (median) following 5 years, and to - 1.68 in those with final height.

#5

Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.

Nature communications2026 Jan 10

RAF activation is essential for MAPK signaling and is mediated by RAS binding and the dephosphorylation of a conserved phosphoserine by the SHOC2-RAS-PP1C complex. MRAS forms a high-affinity SHOC2-MRAS-PP1C (SMP) complex, while canonical RAS isoforms (KRAS, HRAS, NRAS) form analogous but lower-affinity assemblies. Yet, cancers driven by oncogenic KRAS, HRAS, or NRAS remain strongly SHOC2-dependent, suggesting that these weaker complexes contribute to tumorigenesis. To elucidate how canonical RAS proteins form lower-affinity ternary complexes, the cryo-EM structure of the SHOC2-KRAS-PP1C (SKP) complex stabilized by Noonan syndrome mutations is described. The SKP architecture is similar to the SMP complex but forms fewer contacts and buries less surface area due to the absence of MRAS-specific structural features in KRAS that enhance complex stability. RAS inhibitors MRTX1133 and RMC-6236 alter Switch-I/II conformations, thereby blocking SKP assembly more effectively than they disrupt preformed complexes. These RAS inhibitors do not affect SMP formation because they do not bind MRAS. Since MRAS is upregulated in resistance to KRAS inhibition, we characterize a MRAS mutant capable of binding MRTX1133. This MRAS mutant can form an SMP complex, but MRTX1133 blocks its assembly, demonstrating the feasibility of dual SKP and SMP targeting. Overall, our findings define isoform-specific differences in SHOC2-RAS-PP1C complex formation and support a strategy to prevent both SKP and SMP assemblies to overcome resistance in RAS-driven cancers.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.472 artigos no totalmostrando 196

2026

Complex Genetic Architecture in RASopathies: Constitutional PTPN11 and Mosaic RIT1 Pathogenic Variants Underlying Severe Noonan Syndrome With Adult-Onset Acute Myeloid Leukemia.

American journal of medical genetics. Part A
2026

Hypertrophic Cardiomyopathy as a Key Feature of MRAS-Related Noonan Syndrome: New Case and Comprehensive Literature Review.

Prenatal diagnosis
2026

Pulmonary Hypertension in Pediatric Patients with Noonan Syndrome Undergoing Cardiac Catheterization.

Pediatric cardiology
2026

Largely preserved vestibular function despite severe-to-profound hearing loss in Noonan syndrome spectrum disorders.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2026

De Novo RRAS2 Pathogenic Variant in a Fetus With Bilateral Radial Ray and Multisystem Anomalies.

Prenatal diagnosis
2026

Novel Variants in PTPN11, NF1, RASA2, and MAP2K1: Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort.

Clinical genetics
2026

Phosphoproteomics elucidates the functional impact of the PTPN11 p.Asn308Ser variant in a Noonan syndrome pedigree.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
2026

The 9th International RASopathies Symposium.

American journal of medical genetics. Part A
2026

Optimizing Diagnostic Accuracy of Clinical Red Flags in RASopathies.

American journal of medical genetics. Part A
2026

Patient and caregiver perspectives on neurodevelopmental and mental health care for RASopathies.

Therapeutic advances in rare disease
2026

Natural history of coronary aneurysms associated with Noonan's syndrome.

Journal of cardiology cases
2026

Clinical phenotypes and cochlear implant outcomes in patients with PTPN11-associated noonan spectrum disorders: Insights from a genetically screened cohort.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2026

PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variants.

Journal of neuro-oncology
2026

Ossification of Mandibular Central Giant Cell Granuloma (CGCG) in Neurofibromatosis Type 1 Patients.

Cancer diagnosis &amp; prognosis
2026

Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial.

European journal of endocrinology
2026

Irreversible blindness induced by vitamin A deficiency in a child with avoidant/restrictive food intake disorder secondary to Noonan syndrome.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
2026

Automated bone age assessment in rare pediatric growth disorders: a comparative study using Deeplasia.

Frontiers in endocrinology
2026

Atrial Septal Defect Surgical Closure Following Trametinib Utilization in Noonan Syndrome-Associated Hypertrophic Cardiomyopathy.

JACC. Case reports
2026

Noonan Syndrome With Multiple Lentigines Mimicking Obstructive Hypertrophic Cardiomyopathy Treated by Septal Myectomy.

JACC. Case reports
2026

Development and Treatment of Severe Lordoscoliosis in a Patient With Noonan Syndrome With Multiple Lentigines (NSML): A Case Report.

Cureus
2026

Genotype-Phenotype Analysis and New Clinical Findings in a Series of 24 Patients Presenting with Noonan Syndrome and Related Disorders.

Molecular syndromology
2026

Paediatric Retinal Detachment in a Patient With Coexistent Stickler and Noonan Syndromes: The Importance of a Multidisciplinary Approach.

Cureus
2026

Dysregulated TGFβ-ERK Signaling Drives Aberrant Extracellular Matrix Production in Noonan Syndrome-Associated Pulmonary Valve Stenosis.

bioRxiv : the preprint server for biology
2025

Incidence and severity of SARS-CoV-2 infection and vaccine BNT162 side effects in children and adolescents with Noonan Syndrome: a national multicentric study.

Frontiers in pediatrics
2026

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways.

Cells
2026

Advancing Obstetric Care: The Role of Targeted Next-Generation Sequencing in Pregnancies with Structurally Normal Fetuses.

Journal of the Chinese Medical Association : JCMA
2026

Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.

European journal of pediatrics
2026

Neuropathic Pain and Enlarged Nerves in Adult Noonan Syndrome and Noonan Syndrome With Multiple Lentigines: Health-Related Quality of Life and Neurologic Symptoms.

American journal of medical genetics. Part A
2026

Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.

Nature communications
2026

Novel characterization of MRAS mutation-associated Noonan syndrome: Mild adult-onset hypertrophic cardiomyopathy combined with infective endocarditis: A case report.

Medicine
2026

Domain-specific phenotypic profiles in RAF1-related Noonan syndrome.

European journal of human genetics : EJHG
2025

Molecular and Clinical Profiles of Patients with RASopathies: Targeted Next-Generation Sequencing Panel Results and Identification of 14 Novel Disease-Causing Variants.

Molecular syndromology
2026

Noonan Syndrome Spectrum Disorders Predispose to Systemic Lupus Erythematosus: Case Report and Critical Review of the Literature.

American journal of medical genetics. Part A
2025

Understanding Molecular Basis of PTPN11-Related Diseases.

ArXiv
2026

Ventricular arrhythmia and Noonan syndrome with leucine zipperlike transcription regulator 1 mutations: expanding the phenotype with a case report and review of the literature.

Cardiology in the young
2025

Sirolimus for Recurrent Chylothorax and Edema in an Infant with Noonan Syndrome after Resolved Hydrops Fetalis: A Case Report.

AJP reports
2026

CBL-Mutated Juvenile Myelomonocytic Leukaemia With Loss of Heterozygosity on 11q Detected by Microarray: Not Always Such a Favourable Outcome.

International journal of laboratory hematology
2026

Genetic insights and diagnostic challenges in inherited bone marrow failure syndromes: a comprehensive study from a low middle-income country.

Expert review of hematology
2026

Evaluating the Genetic Overlap Between Congenital Heart Disease and Neuroblastoma Risk.

Pediatric blood &amp; cancer
2025

Real-World Evidence of Treatment Patterns and Costs of Turner Syndrome and Noonan Syndrome in the USA.

Hormone research in paediatrics
2025

Protein domain-specific genotype-phenotype correlation study of neurofibromatosis type 1.

Scientific reports
2025

Phenotypic Analysis of Embryos in a Noonan Syndrome Model Mouse With the Rit1 A57G Mutation.

Molecular genetics &amp; genomic medicine
2025

Pulmonary hypertension in patients with Noonan syndrome.

The European respiratory journal
2025

Clinical characteristics of 41 children with hypertrophic cardiomyopathy: A single-center retrospective study.

The Journal of international medical research
2025

Novel use of placental growth hormone in managing intrauterine growth restriction in Noonan syndrome.

Annals of medicine and surgery (2012)
2025

Heterogeneity of Orodental Features in a Family with Noonan Syndrome.

International journal of molecular sciences
2026

Modified Nuss procedure versus Ravitch in concurrent repair of pectus deformity and open-heart surgery.

Asian cardiovascular &amp; thoracic annals
2026

Clinical Spectrum of Noonan Syndrome-Associated Myeloproliferative Disorder.

American journal of hematology
2026

Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome-Associated Obstructive Hypertrophic Cardiomyopathy.

JACC. Case reports
2025

M-Ras distinct activation scenarios: A mechanistic outlook and targeting.

Computational and structural biotechnology journal
2025

Lupus vorax: A rare case of facial tuberculosis in a patient with Noonan syndrome.

IDCases
2025

Diagnostic Value of Exome Sequencing in Isolated Polyhydramnios.

Prenatal diagnosis
2025

Targeted fetal NGS panel reveals genetic conditions in sonographically normal fetuses: Insights from a large cohort study.

PloS one
2025

EndoCompass Project: Research Roadmap for Growth Disorders.

Hormone research in paediatrics
2025

Anesthetic Μanagement of an Emergency Craniotomy in a Patient With Noonan Syndrome: A Case Report.

Cureus
2025

Prevalence of neurodevelopmental and psychiatric disorders in Noonan syndrome: a systematic review and meta-analysis.

European journal of pediatrics
2026

Biventricular Surgical Approach in Noonan Syndrome With Hypertrophic Obstructive Cardiomyopathy.

JACC. Case reports
2026

Long-term effectiveness and safety of daily growth hormone therapy in Japanese children with Noonan syndrome: a post-marketing surveillance study.

Endocrine journal
2025

Analysis of the clinical features of neurocristopathy-related hearing loss and how these relate to outcomes after cochlear implantation.

Scientific reports
2025

Transdiagnostic similarities and distinctions in brain networks associated with autistic social impairments: a prospective cohort study.

Molecular autism
2025

Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy.

World journal of clinical pediatrics
2026

Current opinions on Noonan syndrome and RASopathies.

Current opinion in pediatrics
2025

Optic nerve changes in PTPN11-related Noonan syndrome.

Oman journal of ophthalmology
2025

Clinical and Genetic Characterization of Noonan Syndrome in a Romanian Cohort from Transylvania: Details on PTPN11 c.922A>G Variant and Phenotypic Spectrum.

Diagnostics (Basel, Switzerland)
2025

Germline Predisposition to Pediatric Lymphoid Malignancies: Genetic Tumor Syndromes Identified in a Single-Center Study.

Clinical laboratory
2026

Homozygous LZTR1 Variant Lacking the Second BTB Domain Associated With Bone Marrow Failure and Multiple Congenital Anomalies Distinct From Those of Noonan Syndrome.

Clinical genetics
2025

Anesthetic Management During Post-tonsillectomy Hemorrhage in a Child With Noonan Syndrome: A Case Report.

Cureus
2026

Five Years of Combined Newborn Screening Quantifying TREC and KREC in Switzerland.

The journal of allergy and clinical immunology. In practice
2025

Pathogenesis of Noonan syndrome is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling.

The Journal of clinical endocrinology and metabolism
2026

Langerhans Cell Histiocytosis in Cardiofaciocutaneous Syndrome.

American journal of medical genetics. Part A
2025

Heart transplantation in special patient populations.

JHLT open
2025

Ras-related protein 2 limits vascular smooth muscle cell phenotypic switching and abdominal aortic aneurysm development.

Nature communications
2025

Multivessel Cerebral Occlusion in Noonan Syndrome.

Stroke
2026

Non-RASopathy Genetic Syndromes Identified as the Molecular Cause of Disease in Patients Previously Diagnosed With Noonan Syndrome.

American journal of medical genetics. Part A
2025

Multidisciplinary Treatment of Patients With Noonan Syndrome: A Consensus Statement.

JAMA network open
2025

Out of Sync? Rare Genetic Disease and the Chronopolitics of Care.

Sociology of health &amp; illness
2025

Expanding the Genetic Landscape of RASopathies: Significance of Including NF1 in Targeted Panels.

Molecular syndromology
2025

PRKAG2 Syndrome Presenting With Fetal Sinus Bradycardia and Pulmonary Valve Stenosis as Initial Manifestations.

Prenatal diagnosis
2025

Genotype-phenotype correlations with autism spectrum disorder-related traits in noonan syndrome and noonan syndrome with multiple lentigines: a cross-sectional study.

Molecular autism
2025

Central Conducting Lymphatic Abnormalities in Noonan Syndrome Identified Using SPECT/CT Lymphoscintigraphy.

Nuklearmedizin. Nuclear medicine
2025

Cavitary Lung Abscess Secondary to a Tracheal Bronchus: A Pediatric Patient With Noonan Syndrome.

Cureus
2026

Noonan syndrome and autoimmune hepatitis: patient report and literature review.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

T1w/T2w ratio suggests reduced intracortical myelin content in youth with RASopathies.

medRxiv : the preprint server for health sciences
2025

Transdiagnostic similarities and distinctions in brain networks associated with ASD symptoms: A prospective cohort study.

medRxiv : the preprint server for health sciences
2025

Anesthetic implications of elective cesarean section in a parturient with Noonan syndrome and complex cardiomyopathy: A case report.

Saudi journal of anaesthesia
2025

Noonan Syndrome With Complex Pulmonary Stenosis at High Altitude: Impact of Delayed Diagnosis.

JACC. Case reports
2025

Noonan syndrome with PTPN11 gene variant presenting as isolated short stature: a case report.

Translational pediatrics
2025

Clinical and molecular analysis of seventy-one fetal cases with RASopathies.

European journal of obstetrics, gynecology, and reproductive biology
2025

Prenatal diagnosis of a familial heterozygous pathogenic variant in the PTPN11 gene (c.1510A>G, p.M504V) in a fetus with increased nuchal translucency and pleural effusion and a mother carrier with atypical Noonan syndrome.

Taiwanese journal of obstetrics &amp; gynecology
2025

First Transcatheter Pulmonary Valve Replacement in Tanzania: Feasibility of Advanced Cardiac Interventions in Resource-Limited Settings.

JACC. Case reports
2025

Executive and Social Functioning in Children and Adolescents With Noonan Syndromes: Cognition and Behavior.

JAACAP open
2025

Percutaneous Thoracic Duct Externalization and Autotransfusion in Patients With Lymphatic Failure Due to Elevated Central Venous Pressure.

Circulation. Cardiovascular interventions
2025

Noonan Syndrome and Rett Syndrome in An 8-Year-Old Girl With A Tectal Neoplasm.

JCEM case reports
2025

Imatinib For Treatment of Multifocal Maxillofacial Giant Cell Lesions: A Case Series.

Journal of pediatric hematology/oncology
2025

SHP2 genetic variants in NSML-associated RASopathies disrupt the PZR-IRX transcription factor signaling axis.

Proceedings of the National Academy of Sciences of the United States of America
2025

Case Report: Chylopericardium after Heart Transplantation due to Lymphatic Malformation in a Patient With Noonan Syndrome.

Transplantation proceedings
2025

Mirror syndrome and placental ectopic liver in association with de novo SOS1 variant.

European journal of medical genetics
2025

A child with tuberous sclerosis having Novel NRAS gene mutation.

Journal of family medicine and primary care
2025

Everolimus therapy in an infant with Noonan syndrome with multiple lentigines.

Annals of pediatric cardiology
2025

PZR: Advances in research from cellular signaling Hub to emerging therapeutic targets.

Cellular signalling
2025

Subcortical shape alterations in children with Noonan syndrome spectrum: insights into genotype-phenotype associations.

Cerebral cortex (New York, N.Y. : 1991)
2025

Oral Health and Dental Management Strategies in Noonan Syndrome: A Case Report.

Iranian endodontic journal
2025

Encephalocraniocutaneous lipomatosis-a neuroradiological perspective.

Pediatric radiology
2025

A Noonan Syndrome Mimicking Acute Coronary Syndrome.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
2025

Non-Immune Hydrops Fetalis, Multifocal Chorangiomatosis, and Noonan Syndrome 8.

Congenital anomalies
2025

Increased Prevalence of Psychiatric Disorders in Children with RASopathies: Comparing NF1, Noonan Syndrome Spectrum Disorder, and the General Population.

Genes
2025

Expanding the Phenotypic Spectrum Associated with DPH5-Related Diphthamide Deficiency.

Genes
2025

[Hypertrophy of the lumbosacral nerve roots in Noonan syndrome with multiple lentigines: a case report].

Rinsho shinkeigaku = Clinical neurology
2025

Sequencing validates deep learning models for EHR-based detection of Noonan syndrome in pediatric patients.

NPJ genomic medicine
2026

Cochlear Implantation in a Patient With Noonan Syndrome and Enlarged Cochlear Apertures.

The Laryngoscope
2025

Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders.

International journal of molecular sciences
2025

Abernethy malformation (Type II) presenting in a 6-day-old boy with Noonan syndrome: a case report.

BMC pediatrics
2025

RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.

Cancer research
2025

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.

EMBO molecular medicine
2025

Multiplexed single-cell transcriptomics reveals diverse phenotypic outcomes for pathogenic SHP2 variants.

bioRxiv : the preprint server for biology
2025

Advancing edge-based clustering and graph embedding for biological network analysis: a case study in RASopathies.

Briefings in bioinformatics
2025

Assessing the diagnostic impact of blood transcriptome profiling in a pediatric cohort previously assessed by genome sequencing.

NPJ genomic medicine
2025

Complete commissural agenesis in a child with Noonan-like syndrome with loose anagen hair 2.

Neurogenetics
2025

RAF1 mutation expands the cardiac phenotypic spectrum of Noonan syndrome: A case report.

World journal of cardiology
2025

Role of Histopathology of Skin Lesions in Diagnosing MAP2K1-Positive Cardiofaciocutaneous Syndrome.

The American Journal of dermatopathology
2025

Serum Markers of Bone Turnover and Bone Remodeling in Children with Noonan Syndrome: Genotype-Phenotype Correlation.

Genes
2025

Broad Electrocardiogram Syndromes Spectrum: From Common Emergencies to Particular Electrical Heart Disorders-Part II.

Diagnostics (Basel, Switzerland)
2025

Experience with etilefrine in refractory non-traumatic chylothorax: a case report.

Cardiology in the young
2025

[Analysis of clinical characteristics and NF1 gene variants in a child with Neurofibroma-Noonan syndrome].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Review of 40 genes causing congenital myasthenic syndromes.

Journal of human genetics
2025

RASopathies. Part II: Cutaneous and extracutaneous manifestations.

Journal of the American Academy of Dermatology
2025

Protein-losing enteropathy and multiple vasculature dysplasia in LZTR1-related Noonan syndrome: A case report and review of literature.

World journal of gastroenterology
2025

RASopathies. Part I: Genetics and therapeutic considerations.

Journal of the American Academy of Dermatology
2025

Eosinophilic gastroenteritis in a 14-year-old patient with Noonan syndrome with a PTPN11 variation: a case report.

Journal of medical case reports
2025

Second Trimester Ultrasound Diagnosis of External Hydrocephalus in Two Fetuses with Noonan Syndrome-Case Report Series.

Journal of clinical medicine
2025

Urethral Polyp: A Rare Cause of Urethral Obstruction in Newborns and Children with Special Needs-A Case Series.

Archivos espanoles de urologia
2025

Biallelic SH2B3 germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvement.

European journal of human genetics : EJHG
2025

Severe Nerve Enlargement in SOS2-Related Noonan Syndrome.

American journal of medical genetics. Part A
2025

Recurrent cellulitis associated with lymphoedema in Noonan syndrome: case reports with RIT1 variants and literature review.

Human genome variation
2025

Rapamycin treatment for progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines.

Kardiologia polska
2025

Targeting cardiomyopathies associated with RASopathies: the role of mitogen-activated protein kinase inhibitors and therapeutic challenges.

Pharmacogenetics and genomics
2025

Irritability in children with RASopathies, insights into emotional dysregulation and social impairment.

European child &amp; adolescent psychiatry
2025

ACTC1 Variants Result in Isolated and Syndromic Cardiac Phenotypes.

Clinical genetics
2025

Truncating Variants in RREB1 Cause a Novel RASopathy Syndrome of Congenital Heart Disease, Genitourinary Malformations, and Developmental Delay.

American journal of medical genetics. Part A
2025

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence.

Journal of visualized experiments : JoVE
2025

Co-Occurrence of Dysembryoplastic Neuroepithelial Tumor and Hodgkin Lymphoma in a Patient with Noonan Syndrome and Mutation in the PTPN11 Gene.

Hormone research in paediatrics
2025

Deciphering the structural and dynamic effects of SHP2-E76 mutations: mechanistic insights into oncogenic activation.

BMC chemistry
2025

Molecular Dynamics Simulations of the SPRED2Leu100Pro EVH-1 Domain Complexed with the GAP-Related Domain of Neurofibromin.

International journal of molecular sciences
2025

Noonan Syndrome and Heart Failure in a Postpartum Patient.

Cureus
2025

Chiari 1 malformation in patient with Noonan syndrome: A case report and review of literature.

Surgical neurology international
2025

Expanding the genetic spectrum of short rib polydactyly syndrome: Novel DYNC2H1 variants and functional insights.

Bone
2025

Osteosarcoma Arising in Noonan Syndrome/RASopathy Complex: First Case Report.

Head and neck pathology
2025

Update on the Clinical and Molecular Characterization of Noonan Syndrome and Other RASopathies: A Retrospective Study and Systematic Review.

International journal of molecular sciences
2025

Quantitative T1 Mapping Indicates Elevated White Matter Myelin in Children With RASopathies.

Biological psychiatry
2025

Missense and truncated variants in ERF in individuals with a Noonan-like phenotype without craniosynostosis.

Scientific reports
2025

Rare missense variants in FNDC1 are associated with severe adolescent idiopathic scoliosis.

Journal of medical genetics
2025

Infant with Known Dandy-Walker Malformation and Poor Feeding Found to Have Additional Diagnosis.

AJP reports
2025

Neurofibromatosis-Noonan syndrome: a prospective monocentric study of 26 patients and literature review.

Orphanet journal of rare diseases
2025

Efficacy of Sirolimus in Treating Refractory Lymphatic Malformation in Noonan Syndrome: A Case Study.

JCEM case reports
2025

Modified "Posterior Cervical Lift" Correction of Webbed Neck Deformity.

Plastic and reconstructive surgery. Global open
2025

[A rare placental lesion: Intraparenchymal hepatic heterotopia].

Annales de pathologie
2025

A Novel Description of Immunodeficiency and Immune Dysregulation in a 14-Year-Old Girl with Noonan Syndrome 13.

Journal of clinical immunology
2025

RVOT Stenting and Trametinib in an Infant With Noonan Syndrome, Pulmonary Stenosis, and Hypertrophic Cardiomyopathy.

JACC. Case reports
2025

First steps toward building natural history of diseases computationally: Lessons learned from the Noonan syndrome use case.

American journal of human genetics
2025

Incidental Discovery of Complications of Cryptorchidism During Laparoscopic Inguinal Hernia Surgery.

Case reports in surgery
2025

Cardiovascular aspects of Noonan syndrome and related disorders.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V
2025

Gene signatures and genotype-phenotype correlations of sensorineural hearing loss in Noonan syndrome and related RASopathies.

Scientific reports
2025

Long-Term Efficacy and Safety of Growth Hormone in Children Suffering from Short Stature in China (CGLS): An Open-Label, Multicenter, Prospective and Retrospective, Observational Study.

Advances in therapy
2025

Signaling scaffold Shoc2 regulates lymphangiogenesis by suppressing mTORC1-mediated IFN responses.

bioRxiv : the preprint server for biology
2025

Assessment of Fetal Posterior Fossa Anomalies at 11-13+6 Gestational Weeks in the Midsagittal Cranial Plane by Three-Dimensional Multiplanar Sonography: A Prospective Study.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
2025

Plastic Bronchitis in Noonan Syndrome: Further Evidence Suggesting a Higher Risk of Lymphatic Abnormalities in Individuals Harboring Variants in PTPN11 Residue p.Phe285.

Molecular syndromology
2025

RASopathies and Cardiac Complications: Insights into Mechanisms, Diagnosis, and Innovative Treatments.

Current cardiology reviews
2025

Cardiac MRI Characteristics of Noonan Syndrome Associated With Hypertrophic Cardiomyopathy and Congenital Heart Disease.

Korean journal of radiology
2025

Etiologies of Early-Onset Hearing Impairment in Rwanda.

Genes
2025

Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy.

JACC. Basic to translational science
2025

A familial modeling framework for advancing precision medicine for children with neuropsychiatric disorders.

Developmental medicine and child neurology
2025

Noonan Syndrome Associated with a Patent Foramen Ovale.

The Nigerian postgraduate medical journal
2025

[Clinical characteristics analysis of children with Noonan-like syndrome with loose anagen hair].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

Genetic Insights Into Recurrent Granular Cell Tumours in an Adolescent: The Role of Cytology and Next-Generation Sequencing in the Diagnosis of RASopathies.

Cytopathology : official journal of the British Society for Clinical Cytology
2025

Evaluation of information flows in the RAS-MAPK system using transfer entropy measurements.

eLife
2025

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome.

Frontiers in pediatrics
2025

[Perioperative management of cochlear implantation and analysis on the influencing factors of efficacy in patients diagnosed as hereditary syndromic hearing loss].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2026

Heart Transplantation Outcomes in Pediatric Patients with Noonan Syndrome: An Institutional Case Series.

Pediatric cardiology
2025

Noonan syndrome and parasternal pericardiocentesis.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
2025

Noonan Syndrome, Cancer Risk, and Growth Hormone Treatment.

Journal of clinical research in pediatric endocrinology
2025

Aberrant ERK signaling in astrocytes impairs learning and memory in RASopathy-associated BRAF mutant mouse models.

The Journal of clinical investigation
2025

Health outcomes and drug utilisation in children with Noonan syndrome: a European cohort study.

Orphanet journal of rare diseases
2025

Germline Variants in Pediatric Cancer : Based on Oncogenic Pathways.

Journal of Korean Neurosurgical Society
2025

Hypertrophic cardiomyopathy combined with renal and adrenal aplasia in a male with Noonan syndrome from RAF1 variant.

ESC heart failure
2025

Hypertrophic cardiomyopathy: prevalence of disease-specific red flags.

European heart journal
2025

Case Report: A rare case of Noonan syndrome with multiple lentigines manifesting as cardiac enlargement.

Frontiers in cardiovascular medicine
2024

Impact of pubertal timing on growth progression and final height in subjects affected by RASopathies.

Frontiers in endocrinology
2025

Beyond the postmortem diagnosis of hypertrophic cardiomyopathy: a genetic approach guided by clinical and morphological features in Noonan syndrome.

Revista espanola de cardiologia (English ed.)
2025

Endoscopic Mitral Surgery in Noonan Syndrome-Case Report and Considerations.

Journal of clinical medicine
2024

GH Therapy in Non-Growth Hormone-Deficient Children.

Children (Basel, Switzerland)
2025

[Growth and development patterns of Noonan syndrome and advances in the treatment of short stature].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2025

Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency.

Annals of pediatric endocrinology &amp; metabolism
2025

Longitudinal outcomes in Noonan syndrome.

Genetics in medicine : official journal of the American College of Medical Genetics
2024

Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genes.

medRxiv : the preprint server for health sciences
2025

Severe coronary artery ectesia in a paediatric patient with Noonan syndrome presenting for transcatheter pulmonary valve placement.

Cardiology in the young
2024

Irritability in Children with Rasopathies, Insights into Emotional Dysregulation and Social Skills Impairments.

Research square
Ver todos os 1.472 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Noonan.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Noonan

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Novel Variants in PTPN11, NF1, RASA2, and MAP2K1: Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort.
    Clinical genetics· 2026· PMID 41854160mais citado
  2. Phosphoproteomics elucidates the functional impact of the PTPN11 p.Asn308Ser variant in a Noonan syndrome pedigree.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences· 2026· PMID 41843963mais citado
  3. Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways.
    Cells· 2026· PMID 41597264mais citado
  4. Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.
    European journal of pediatrics· 2026· PMID 41577878mais citado
  5. Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.
    Nature communications· 2026· PMID 41519889mais citado
  6. Targeting Interleukin-8-Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome.
    Circulation· 2026· PMID 41988707recente
  7. Clinical and Genetic Characterization of Noonan Syndrome in a Colombian Pediatric Cohort.
    J Clin Res Pediatr Endocrinol· 2026· PMID 41988663recente
  8. A Phase II Basket Trial of Vosoritide in Children with RASopathies, ACAN and NPR2 Deficiency.
    J Clin Endocrinol Metab· 2026· PMID 41967490recente
  9. Sleep disorders in genetic syndromes associated with congenital heart disease: A comprehensive review.
    Sleep Med· 2026· PMID 41955722recente
  10. Signaling scaffold Shoc2 regulates lymphangiogenesis by suppressing mTORC1-mediated IFN responses.
    Cell Death Differ· 2026· PMID 41946973recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:648(Orphanet)
  2. MONDO:0018997(MONDO)
  3. GARD:10955(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1543446(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Noonan
Compêndio · Raras BR

Síndrome Noonan

ORPHA:648 · MONDO:0018997
Prevalência
1-5 / 10 000
Herança
Autosomal dominant, Autosomal recessive
CID-10
Q87.1 · Síndromes com malformações congênitas associadas predominantemente com nanismo
CID-11
Ensaios
18 ativos
Medicamentos
3 registrados
Início
Antenatal, Childhood, Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0028326
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades